Topics

U.S. Securities and Exchange Commission
Taking aim at short-sellers, but misfiring
Taking aim at short-sellers, but misfiring

Northwest Biotherapeutics, a Bethesda, Md., firm with a purported cancer vaccine in development, has been in a long, bitter battle with short-sellers of its shares. It also has implied that Adam Feuerstein, a reporter for TheStreet.com, may be in cahoots with the shorts.  Recently, Northwest has acquired some very high-profile support for this viewpoint. The mightiest shot came over the weekend from Steven Pearlstein, a Pulitzer Prize-winning business columnist for the Washington Post, who built Northwest's stock-trading travails into a broad case against short-selling in general and took a shot at Feuerstein as well. He drew much of his ammunition from a letter submitted to...

Loading